Bio Europe, Europe’s largest platform designed for companies in the biotech and pharma sectors to meet and forge partnerships. Last year, the event hosted more than 4’400 visitors from 61 countries and 2300 companies. Over 27’300 one-to-one partnering meetings took place.
This year, the event will take place in a digital format from 26th to 29th October. Participants will have the opportunity to organise one-to-one sessions, attend workshops, watch company presentations and listen to keynote speeches and panel discussions from leading industry players. Attendees will also expand their contacts by networking with participants from different calibres.
For start-ups, the event provides a venue to pitch their innovation to decision-makers, including investors, in the life science industry worldwide. 15 Swiss biotech start-ups will represent Switzerland at the Swiss Pavilion. The presence of twelve of them is supported by Innosuisse through its international trade fair program.
The start-ups at the Swiss Pavilion are:
Adiposs: a revolutionary medical imaging product capable of detecting cachexia, a syndrome affecting cancer patients.
Anjarium Biosciences: is transforming exosomes from cellular message couriers to potent therapeutic carriers for debilitating diseases. The start-up’s Hybridosome platform creates unmatched advantages in the realm of engineering exosomes to address the therapeutic areas of cancer and rare genetic diseases.
CDR-Life: a pipeline of first-in-class tumour-targeted immunotherapies and best-in-class retina disease therapy.
Juvabis: the UZH spinoff is developing Apramycin, an aminoglycoside antibiotic to fight against antimicrobial resistance.
NovaGo: regenerative therapies for diseases of the central nervous system such as stroke and spinal cord injury.
Scailyte: uses artificial intelligence to discover new ultrasensitive biomarkers and develop in-vitro diagnostics (IVD) based on single-cell technologies and their proprietary single-cell data analysis platform ScaiVision.
Abologix: best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein
Acthera: proprietary lipids able to release active ingredients, such as small molecules
Cellestia Biotech: first-in-class cancer drugs based on its innovative discovery platform targeting leukaemia, lymphoma and solid tumours.
LifeMatrix: next-generation biomimetic implants for cardiovascular indications that can grow and regenerate with the patient.
Neurix: offers alternatives to traditional R&D in the central nervous system. NEURIX provides researchers with customised services including MiniBrains, an innovative in vitro neural tissue in 3D.
TargImmune Therapeutics: focuses on drug development using novel targeted onco-immunotherapies destroying cancer cells while simultaneously eliciting an immune response against the cancer cells.
Avrion Therapeutics: precision gene therapies for neurodegenerative diseases. Avrion's first clinical candidate gene therapy product, is for the treatment of a fatal neuromuscular disorder.
Oculis: develops novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye
Versantis: is a clinical-stage biotech company focused on the development of novel therapeutics in rare liver and pediatric diseases.
Abologix, Acthera, Adiposs, Anjarium, CDR-Life, Cellestia Biotech, Juvabis, LifeMatrix, Neurix, NovaGo, Scailyte and Targimmune are supported by Innosuisse. The Swiss Pavilion at Bio Europe is organised by the Swiss Biotech Association and Switzerland Global Enterprise. Apart from the companies, Biopôle as well as several consulting companies will exhibit at the pavilion.